These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 34089876)

  • 1. Treatment Patterns and Outcomes, Before and After Humulin R U-500 Initiation, Among High-Dose Type 2 Diabetes Mellitus Patients in the United States.
    Hood RC; Borra S; Fan L; Pollom RD; Huang A; Chen J
    Endocr Pract; 2021 Aug; 27(8):798-806. PubMed ID: 34089876
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment Patterns and Outcomes Before and After Humulin R U-500 Initiation Among US Patients with Type 2 Diabetes Previously Prescribed ≤ 200 Units/day of U-100 Insulin.
    Chen J; Borra S; Huang A; Fan L; Pollom RD; Hood RC
    Diabetes Ther; 2022 Mar; 13(3):465-479. PubMed ID: 35190970
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment patterns and outcomes before and after human regular U-500 insulin initiation via KwikPen® among US veterans with type 2 diabetes mellitus.
    Chen J; Borra S; Fan L; Huang A; Patel D; Juneja R
    J Diabetes Complications; 2021 Oct; 35(10):107995. PubMed ID: 34364779
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TWO TREATMENT APPROACHES FOR HUMAN REGULAR U-500 INSULIN IN PATIENTS WITH TYPE 2 DIABETES NOT ACHIEVING ADEQUATE GLYCEMIC CONTROL ON HIGH-DOSE U-100 INSULIN THERAPY WITH OR WITHOUT ORAL AGENTS: A RANDOMIZED, TITRATION-TO-TARGET CLINICAL TRIAL.
    Hood RC; Arakaki RF; Wysham C; Li YG; Settles JA; Jackson JA
    Endocr Pract; 2015 Jul; 21(7):782-93. PubMed ID: 25813411
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost, healthcare resource utilization, and adherence of individuals with diabetes using U-500 or U-100 insulin: a retrospective database analysis.
    Eby EL; Wang P; Curtis BH; Xie J; Haldane DC; Idris I; Peters AL; Hood RC; Jackson JA
    J Med Econ; 2013; 16(4):529-38. PubMed ID: 23363330
    [TBL] [Abstract][Full Text] [Related]  

  • 6. OPTIMIZED HUMAN REGULAR U-500 INSULIN TREATMENT IMPROVES β-CELL FUNCTION IN SEVERELY INSULIN-RESISTANT PATIENTS WITH LONG-STANDING TYPE 2 DIABETES AND HIGH INSULIN REQUIREMENTS.
    Mari A; Rosenstock J; Ma X; Li YG; Jackson JA
    Endocr Pract; 2015 Dec; 21(12):1344-52. PubMed ID: 26307903
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Initiation of human regular U-500 insulin use is associated with improved glycemic control: a real-world US cohort study.
    Eby EL; Curtis BH; Gelwicks SC; Hood RC; Idris I; Peters AL; Bergenstal RM; Jackson JA
    BMJ Open Diabetes Res Care; 2015; 3(1):e000074. PubMed ID: 25969741
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patient-reported outcomes in transition from high-dose U-100 insulin to human regular U-500 insulin in severely insulin-resistant patients with type 2 diabetes: analysis of a randomized clinical trial.
    Kabul S; Hood RC; Duan R; DeLozier AM; Settles J
    Health Qual Life Outcomes; 2016 Sep; 14(1):139. PubMed ID: 27716283
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Effect of Prestudy Insulin Therapy on Safety and Efficacy of Human Regular U-500 Insulin by Pump or Injection: A Posthoc Analysis.
    Hood RC; Chen Y; Sindelar DK; Ly T; Juneja R; Pollom RD; Ilag L; Wysham C
    Endocr Pract; 2021 Aug; 27(8):783-789. PubMed ID: 33515757
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment Patterns, Adherence, and Persistence Associated With Human Regular U-500 Insulin: A Real-World Evidence Study.
    Chen J; Kao CY; He X; Fan L; Jackson JA; Juneja R
    Diabetes Spectr; 2020 Aug; 33(3):264-272. PubMed ID: 32848348
    [No Abstract]   [Full Text] [Related]  

  • 11. EFFECT OF TOTAL DAILY DOSE ON EFFICACY, DOSING, AND SAFETY OF 2 DOSE TITRATION REGIMENS OF HUMAN REGULAR U500 INSULIN IN SEVERELY INSULIN-RESISTANT PATIENTS WITH TYPE 2 DIABETES.
    Wysham C; Hood RC; Warren ML; Wang T; Morwick TM; Jackson JA
    Endocr Pract; 2016 Jun; 22(6):653-65. PubMed ID: 26789342
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Healthcare costs and adherence associated with human regular U-500 versus high-dose U-100 insulin in patients with diabetes.
    Eby EL; Zagar AJ; Wang P; Curtis BH; Xie J; Haldane DC; Idris I; Peters AL; Hood RC; Jackson JA
    Endocr Pract; 2014 Jul; 20(7):663-70. PubMed ID: 24449672
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Which people with diabetes are treated with a disposable, half-unit insulin pen? A real-world, retrospective, database study in Spain.
    Ampudia-Blasco FJ; Duque N; Artime E; Caveda E; Spaepen E; Díaz-Cerezo S; de Santos MR; Velasco DC; Bahíllo-Curieses MP
    Endocrinol Diabetes Metab; 2023 Nov; 6(6):e451. PubMed ID: 37715339
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment Dosing Patterns and Clinical Outcomes for Patients with Type 2 Diabetes Starting or Switching to Treatment with Insulin Glargine (300 Units per Milliliter) in a Real-World Setting: A Retrospective Observational Study.
    Gupta S; Wang H; Skolnik N; Tong L; Liebert RM; Lee LK; Stella P; Cali A; Preblick R
    Adv Ther; 2018 Jan; 35(1):43-55. PubMed ID: 29313285
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical use of U-500 regular insulin: review and meta-analysis.
    Reutrakul S; Wroblewski K; Brown RL
    J Diabetes Sci Technol; 2012 Mar; 6(2):412-20. PubMed ID: 22538155
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of a Conservative Pharmacist-led U-500R Insulin Management Protocol in the Primary Care Setting.
    Dumont C; Fitzgerald L; Valdez CA
    J Prim Care Community Health; 2020; 11():2150132720973827. PubMed ID: 33218271
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mealtime 50/50 basal + prandial insulin analogue mixture with a basal insulin analogue, both plus metformin, in the achievement of target HbA1c and pre- and postprandial blood glucose levels in patients with type 2 diabetes: a multinational, 24-week, randomized, open-label, parallel-group comparison.
    Robbins DC; Beisswenger PJ; Ceriello A; Goldberg RB; Moses RG; Pagkalos EM; Milicevic Z; Jones CA; Sarwat S; Tan MH
    Clin Ther; 2007 Nov; 29(11):2349-64. PubMed ID: 18158076
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A primer on concentrated insulins: what an internist should know.
    Barnosky A; Shah L; Meah F; Emanuele N; Emanuele MA; Mazhari A
    Postgrad Med; 2016 May; 128(4):381-90. PubMed ID: 26924668
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics and Pharmacodynamics of Human Regular U-500 Insulin Administered via Continuous Subcutaneous Insulin Infusion Versus Subcutaneous Injection in Adults With Type 2 Diabetes and High-Dose Insulin Requirements.
    Ma X; Benson CT; Prescilla R; Zhang S; Linnebjerg H; LaBell ES; Morrow LA; Jackson JA; Nguyen A; Ilag LL; Johnson JL; Leishman D
    J Diabetes Sci Technol; 2022 Mar; 16(2):401-407. PubMed ID: 33242998
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Real-world persistence, adherence, health care resource utilization, and costs in people with type 2 diabetes switching from a first-generation basal insulin to a second-generation (insulin glargine 300 U/mL) vs an alternative first-generation basal insulin.
    Wright EE; Malone DC; Trujillo JM; Gill J; Huse S; Li X; Zhou FL; Preblick R; Reid T
    J Manag Care Spec Pharm; 2022 Jun; 28(6):592-603. PubMed ID: 35352995
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.